European Patent Office: These 63 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: European Patent Office Patent 1,613,297
Patent Title: DISPOSITIF THERAPEUTIQUE TRANSDERMIQUE DOTE D'UNE MATRICE DE POLYSILOXANE CONTENANT DE LA CAPSAICINE (THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN)

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: European Patent Office Patent 1,617,832
Patent Title: COMPOSITIONS INFLUANT SUR LA PERTE DE POIDS (COMPOSITIONS FOR AFFECTING WEIGHT LOSS)

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-seven patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: European Patent Office Patent 1,870,096
Patent Title: Compositions pour influencer la perte de poids (Compositions for affecting weight loss)

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-seven patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: European Patent Office Patent 2,316,456
Patent Title: Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids (Compositions for affecting weight loss comprising an opioid antagonist and bupropion)

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-seven patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: European Patent Office Patent 3,281,628
Patent Title: COMPOSITIONS POUR INFLUENCER LA PERTE DE POIDS (COMPOSITIONS FOR AFFECTING WEIGHT LOSS)

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-seven patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: European Patent Office Patent 1,622,880
Patent Title: DIHYDROQUINAZOLINES SUBSTITUEES A PROPRIETES ANTIVIRALES (SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES)

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: istradefylline
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2023
Generic Entry Controlled by: European Patent Office Patent 1,626,049
Patent Title: Microcristal de (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (Microcrystal of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione)

NOURIANZ is a drug marketed by Kyowa Kirin. There are four patents protecting this drug.

This drug has sixty-three patent family members in eighteen countries.

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the istradefylline profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,629,007
Patent Title: NOUVEAUX PEPTIDES SE FIXANT AU RECEPTEUR DE L'ERYTHROPOIETINE (NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR)

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,628,967
Patent Title: COMPOSÉS IMMUNOSUPPRESSEURS ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,633,336
Patent Title: COMPOSES IMMUNOSUPPRESSEURS ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,638,551
Patent Title: COMPOSES IMMUNOSUPPRESSEURS ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,644,367
Patent Title: COMPOSITIONS ET COMPOSES IMMUNOSUPPRESSEURS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 2,514,743
Patent Title: COMPOSÉS D'IMMUNOSUPPRESSION ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 2,644,195
Patent Title: Composes Immunosuppresseurs et Compositions (Immunosuppressant Compounds and Compositions)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 3,138,835
Patent Title: COMPOSES IMMUNOSUPPRESSEURS ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: European Patent Office Patent 3,272,736
Patent Title: COMPOSÉS D'IMMUNOSUPPRESSION ET COMPOSITIONS (IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: European Patent Office Patent 1,631,257
Patent Title: COMPOSITIONS OPHTALMOLOGIQUES CONTENANT UNE ASSOCIATION SYNERGIQUE DE DEUX POLYMERES (OPHTHALMIC COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF TWO POLYMERS)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: European Patent Office Patent 2,116,227
Patent Title: Compositions ophtalmologiques contenant une association synergique de deux polymères (Ophthalmic compositions containing a synergistic combination of two polymers)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: European Patent Office Patent 2,361,610
Patent Title: Compositions ophtalmologiques contenant une association synergique de deux polymères (Ophthalmic compositions containing a synergistic combination of two polymers)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: European Patent Office Patent 2,526,929
Patent Title: Compositions ophthalmologiques contentant une association synergique de deux polymères (Ophthalmic compositions containing a synergistic combination of two polymers)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: European Patent Office Patent 3,028,692
Patent Title: COMPOSITIONS OPHTHALMIQUES CONTENANT UNE ASSOCIATION SYNERGIQUE DE DEUX POLYMERES (OPHTHALMIC COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF TWO POLYMERS)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: European Patent Office Patent 1,654,263
Patent Title: SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: European Patent Office Patent 1,654,263
Patent Title: SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: European Patent Office Patent 1,654,263
Patent Title: SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: European Patent Office Patent 1,654,263
Patent Title: SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: European Patent Office Patent 1,646,389
Patent Title: DERIVES DE PYRIMIDINE-2, 4-DIONE UTILISES COMME ANTAGONISTES DU RECEPTEUR D'HORMONE LIBERANT DE LA GONADOTROPHINE (PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS)

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: European Patent Office Patent 1,646,389
Patent Title: DERIVES DE PYRIMIDINE-2, 4-DIONE UTILISES COMME ANTAGONISTES DU RECEPTEUR D'HORMONE LIBERANT DE LA GONADOTROPHINE (PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS)

ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: formoterol fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: European Patent Office Patent 1,660,035
Patent Title: COMPOSITIONS LIQUIDES COMPRENANT DU FORMOTEROL (LIQUID COMPOSITIONS COMPRISING FORMOTEROL)

PERFOROMIST is a drug marketed by Mylan Speclt.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering PERFOROMIST

See drug price trends for PERFOROMIST.

The generic ingredient in PERFOROMIST is formoterol fumarate. There are nineteen drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the formoterol fumarate profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: European Patent Office Patent 1,663,996
Patent Title: DERIVES DE (THIO) CARBAMOYL-CYCLOHEXANE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS D3/D2 ((THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)

VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 1,660,531
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,107,069
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,065
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,066
Patent Title: Nouveaux derives de l'insuline (Novel insulin derivatives)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,275,439
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,287,184
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 1,660,531
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,107,069
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,065
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,066
Patent Title: Nouveaux derives de l'insuline (Novel insulin derivatives)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,275,439
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,287,184
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 1,660,531
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,107,069
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,065
Patent Title: NOUVEAUX DERIVES DE L'INSULINE (NOVEL INSULIN DERIVATIVES)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,264,066
Patent Title: Nouveaux derives de l'insuline (Novel insulin derivatives)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,275,439
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: European Patent Office Patent 2,287,184
Patent Title: Nouveaux dérivés d'insuline (Novel insulin derivatives)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMALOG KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG KWIKPEN

See drug price trends for HUMALOG KWIKPEN.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro recombinant profile page.

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMALOG MIX 50/50 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN

The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMALOG MIX 75/25 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN

The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMULIN 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN 70/30

The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

Generic name: insulin susp isophane recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMULIN N is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN N

See drug price trends for HUMULIN N.

The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin susp isophane recombinant human profile page.

Generic name: insulin human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: European Patent Office Patent 1,656,170
Patent Title: APPAREIL DE DISTRIBUTION DE MEDICAMENTS A TRIPLE FILETAGE PRESENTANT UN AVANTAGE MECANIQUE (MEDICATION DISPENSING APPARATUS WITH TRIPLE SCREW THREADS FOR MECHANICAL ADVANTAGE)

HUMULIN R is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN R

See drug price trends for HUMULIN R.

The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin human profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: European Patent Office Patent 1,660,482
Patent Title: ETHYLESTER-METHANSULFONATE D'ACIDE 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHIL-1H - -BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO]-PROPIONIQUE ET SON UTILISATION EN TANT QUE MEDICAMENT (3-[(2-{ 4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO] -METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO -PROPIONIC ACID ETHYL ESTER METHANE SULPHONATE AND USE THEREOF AS A MEDICAMENT)

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: European Patent Office Patent 2,060,569
Patent Title: Hemihydrate de méthanesulfonate d'éthylester d'acide 3-[(2-{[4-hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique et son utilisation comme médicament (Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulfonate hemihydrate and its use as a medicament)

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: fluticasone propionate; salmeterol xinafoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2023
Generic Entry Controlled by: European Patent Office Patent 1,699,434
Patent Title: PROCEDE DE PREPARATION D'UN MEDICAMENT (PROCESS FOR PREPARING A MEDICAMENT)

AIRDUO RESPICLICK is a drug marketed by Teva Pharm. There are sixteen patents protecting this drug.

This drug has four hundred and nineteen patent family members in thirty-seven countries. There has been litigation on patents covering AIRDUO RESPICLICK

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

Generic name: retapamulin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 03, 2023
Generic Entry Controlled by: European Patent Office Patent 1,663,220
Patent Title: NOUVEAU PROCEDE POUR LA FABRICATION DE DERIVES DE LA PLEUROMUTILINE (NOVEL PROCESS FOR THE PREPARATION OF PLEUROMUTILIN DERIVATIVES)

ALTABAX is a drug marketed by Almirall. There are two patents protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. One supplier is listed for this generic product. Additional details are available on the retapamulin profile page.

Generic name: retapamulin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 03, 2023
Generic Entry Controlled by: European Patent Office Patent 2,181,995
Patent Title: Sels et forme crystalline de mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate (Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate)

ALTABAX is a drug marketed by Almirall. There are two patents protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. One supplier is listed for this generic product. Additional details are available on the retapamulin profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: European Patent Office Patent 1,670,482
Patent Title: UTILISATION DE CICLESONIDE DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES (USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES)

ALVESCO is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ALVESCO.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: European Patent Office Patent 1,670,482
Patent Title: UTILISATION DE CICLESONIDE DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES (USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES)

OMNARIS is a drug marketed by Covis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in twelve countries.

See drug price trends for OMNARIS.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: European Patent Office Patent 1,670,482
Patent Title: UTILISATION DE CICLESONIDE DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES (USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES)

ZETONNA is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ZETONNA.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,667,986
Patent Title: SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL ET SON PROCEDE DE PREPARATION (DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF)

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: European Patent Office Patent 1,678,201
Patent Title: CHLORHYDRATES D'UN DERIVE DE GLYCOPEPTIDE PHOSPHONATE (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE)

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: European Patent Office Patent 2,495,251
Patent Title: CHLORHYDRATES D'UN DERIVE DE GLYCOPEPTIDE PHOSPHONATE (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE)

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: European Patent Office Patent 1,677,792
Patent Title: PREPARATION SOLIDE COMPRENANT DE LA PIOGLITAZONE, DU GLIMEPIRIDE ET UN ESTER D'ACIDE GRAS DE POLYOXYETHYLENE SORBITAN (SOLID PREPARATION COMPRISING PIOGLITAZONE, GLIMEPIRIDE AND A POLYOXYETHYLENE SORBITAN FATTY ACID ESTER)

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: European Patent Office Patent 1,708,690
Patent Title: TRAITEMENT DE LA PHÉNYLCÉTONURIE AVEC DE LA BH4 (TREATMENT OF PHENYLKETONURIA WITH BH4)

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: European Patent Office Patent 3,138,566
Patent Title: TRAITEMENT DE LA PHÉNYLCÉTONURIE AVEC DE LA BH4 (TREATMENT OF PHENYLKETONURIA WITH BH4)

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: European Patent Office Patent 3,977,999
Patent Title: TRAITEMENT DE LA PHÉNYLCÉTONURIE AVEC BH4 (TREATMENT OF PHENYLKETONURIA WITH BH4)

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: European Patent Office Patent 1,682,098
Patent Title: COMPOSITION PURGATIVE POUR LE COLON A AGENT DE LIAISON SOLUBLE (COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT)

OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

See drug price trends for OSMOPREP.

The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.

Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: European Patent Office Patent 2,308,476
Patent Title: Composition purgative pour le colon à agent de liaison soluble (Colonic purgative composition with soluble binding agent)

OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

See drug price trends for OSMOPREP.

The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 1,687,019
Patent Title: FORMULATIONS PEPTIDIQUES A BASE DE PROPYLENE GLYCOL OPTIMALES POUR LA PRODUCTION ET L'UTILISATION DANS DES DISPOSITIFS D'INJECTION (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES)

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 2,394,656
Patent Title: Formulations de peptide contenant du propylèneglycol qui sont optimales pour la production et l'utilisation dans des dispositifs d'injection (Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices)

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 3,300,721
Patent Title: FORMULATIONS DE PEPTIDES CONTENANT DU PROPYLÈNE GLYCOL QUI SONT OPTIMALES POUR LA PRODUCTION ET DESTINÉES À ÊTRE UTILISÉES DANS DES DISPOSITIFS D'INJECTION (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES)

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 1,687,019
Patent Title: FORMULATIONS PEPTIDIQUES A BASE DE PROPYLENE GLYCOL OPTIMALES POUR LA PRODUCTION ET L'UTILISATION DANS DES DISPOSITIFS D'INJECTION (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES)

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 2,394,656
Patent Title: Formulations de peptide contenant du propylèneglycol qui sont optimales pour la production et l'utilisation dans des dispositifs d'injection (Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices)

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: European Patent Office Patent 3,300,721
Patent Title: FORMULATIONS DE PEPTIDES CONTENANT DU PROPYLÈNE GLYCOL QUI SONT OPTIMALES POUR LA PRODUCTION ET DESTINÉES À ÊTRE UTILISÉES DANS DES DISPOSITIFS D'INJECTION (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES)

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: European Patent Office Patent 1,689,370
Patent Title: PROCEDE POUR PRODUIRE UNE COMPOSITION PHARMACEUTIQUE SOLIDE A APPLICATION ORALE COMPRENANT DU 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide (METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide)

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: European Patent Office Patent 1,704,141
Patent Title: DERIVES NITROOXY DE PROSTAGLANDINES (PROSTAGLANDIN NITROOXYDERIVATIVES)

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: European Patent Office Patent 3,002,277
Patent Title: DÉRIVÉS DE PROSTAGLANDINE (PROSTAGLANDIN DERIVATIVES)

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: European Patent Office Patent 3,643,702
Patent Title: DÉRIVÉS DE PROSTAGLANDINE (PROSTAGLANDIN DERIVATIVES)

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,715,843
Patent Title: COMBINAISON D'ANTAGONISTE DE RECEPTEUR NMDA ET D'INHIBITEUR MAO OU GADPF POUR LE TRAITEMENT D'AFFECTIONS LIEES AU SYSTEME NERVEUX CENTRAL (COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND A MAO-INHIBITOR OR A GADPH-INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM-RELATED CONDITIONS)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,727,538
Patent Title: METHODES ET COMPOSITIONS DESTINEES AU TRAITEMENT DE L'EPILEPSIE, DES TROUBLES EPILEPTIQUES ET D'AUTRES TROUBLES DU SYSTEME NERVEUX CENTRAL (COMBINATION OF AN NMDA RECEPTOR ANTAGONIST AND AN ANTI-EPILEPTIC DRUG FOR THE TREATMENT OF EPILEPSY AND OTHER CNS DISORDERS)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,734,920
Patent Title: COMBINAISON D'UN ANTAGONISTE DU RECEPTEUR NMDA ET D'UN INHIBITEUR MAO OU GADPF POUR LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES (COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND AN MAO-INHIBITOR OR A GADPH-INHIBITOR FOR THE TREATMENT OF PSYCHIATRIC CONDITIONS)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,789,028
Patent Title: COMPOSITIONS POUR LE TRAITEMENT DE LA DOULEUR NOCICEPTIVE (COMPOSITIONS FOR TREATING NOCICEPTIVE PAIN)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,827,385
Patent Title: COMPOSITION PHARMACEUTIQUE CONTENANT MEMANTINE DANS UNE FORME À LIBERATION PROLONGÉE POUR LE TRATIEMENT DE DEMENTIA (PHARMACEUTICAL COMPOSITION COMPRISING MEMANTINE IN AN EXTENDED DOSAGE RELEASE FORM FOR USE IN THE TREATMENT OF DEMENTIAS)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,874,282
Patent Title: PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DES PATHOLOGIES ASSOCIEES AU SYSTEME NERVEUX CENTRAL (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 2,243,475
Patent Title: Combinaison de mémantine et donépézil pour le traitement de conditions relatives au SNC (Combination of memantine and donepezil for treatment of CNS disorders)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 2,343,057
Patent Title: Procédé et composition pour l'administration d'un antagoniste du récepteur NMDA à un sujet (Method and composition for administering an NMDA receptor antagonist to a subject)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: fosdenopterin hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,664,317
Patent Title: Utilisation du précurseur Z pour produire un agent servant à traiter la déficience humaine en cofacteur molybdène (Use of precursor Z for the production of a means for therapy of human molybdenum cofactor deficiency)

NULIBRY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

This drug has ten patent family members in ten countries.

The generic ingredient in NULIBRY is fosdenopterin hydrobromide. One supplier is listed for this generic product. Additional details are available on the fosdenopterin hydrobromide profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 1,716,122
Patent Title: MODULATEURS DE TRANSPORTEURS DE TYPE CASSETTE DE LIAISON A L'ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 1,945,632
Patent Title: MODULATEURS HÉTÉROCYCLIQUES DE TRANSPORTEURS À CASSETTE LIANT L' ATP (HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 2,395,002
Patent Title: COMPOSITION PHARMACEUTIQUE CONTENANT UN MODULATEUR HÉTÉROCYCLIQUE DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC MODULATOR OF ATP-BINDING CASSETTE TRANSPORTERS.)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 2,404,919
Patent Title: Composé hétérocyclique en tant qu'un modulateur de transporteurs de cassette à liaison ATP (Heterocyclic compound useful as a modulator of ATP-binding cassette transporters.)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 2,774,925
Patent Title: Modulateurs hétérocycliques de transporteurs à cassette liant l'ATP (Heterocyclic modulators of ATP-binding cassette transporters)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 3,208,272
Patent Title: MODULATEURS HÉTÉROCYCLIQUES DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 3,219,709
Patent Title: COMPOSÉ INTERMÉDIAIRE DE MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (INTERMEDIATE COMPOUND OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: European Patent Office Patent 3,696,174
Patent Title: MODULATEURS HÉTÉROCYCLIQUES DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: European Patent Office Patent 1,755,565
Patent Title: CAPSULE MOLLE DE GELATINE COMPRENANT DE L'ACIDE GRAS POLYINSATURE OMEGA-3 (SOFT GELATIN CAPSULE COMPRISING OMEGA-3 POLYUNSATURATED FATTY ACID)

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: European Patent Office Patent 3,289,750
Patent Title: RÉCUPÉRATION DE CLÉ PRIVÉE AUTONOME (AUTONOMOUS PRIVATE KEY RECOVERY)

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: European Patent Office Patent 1,718,288
Patent Title: FORMULATIONS SOLIDES D'OSPEMIFENE (SOLID FORMULATIONS OF OSPEMIFENE)

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: European Patent Office Patent 2,286,806
Patent Title: Formulations solides d'ospemifene (Solid formulations of ospemifene)

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: European Patent Office Patent 1,725,234
Patent Title: TRAITEMENT A FAIBLES EFFETS SECONDAIRES CONTRE DES AFFECTIONS LIEES A L'HYPERLIPIDEMIE ET L'HYPERCHOLESTEROLEMIE (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: European Patent Office Patent 1,725,569
Patent Title: PRODROGUES DE PIPERAZINE ET AGENTS ANTIVIRAUX DE PIPERIDINE SUBSTITUEE (PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS)

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 1,730,131
Patent Title: DERIVES DU BENZOL SUBSTITUES PAR UN GLUCOPYRANOSYLE,, MEDICAMENTS RENFERMANT CES COMPOSES, LEUR UTILISATION ET LEUR PROCEDE DE PRODUCTION (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF)

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 1,828,216
Patent Title: DERIVES DE BENZENE SUBSTITUES PAR GLUCOPYRANOSYLE, MEDICAMENTS CONTENANT CES COMPOSES, LEUR UTILISATION ET LEUR PROCEDE DE FABRICATION (GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE)

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,295,422
Patent Title: Dérivés de benzol substitués par glucopyranosyl, médicament contenant ces composés, leur utilisation et leur procédé de fabrication (Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production)

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,360,164
Patent Title: Derives de benzene substitues par glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de fabrication (Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof)

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,360,165
Patent Title: Derives du benzol substitues par un glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de production (Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture)

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 1,730,131
Patent Title: DERIVES DU BENZOL SUBSTITUES PAR UN GLUCOPYRANOSYLE,, MEDICAMENTS RENFERMANT CES COMPOSES, LEUR UTILISATION ET LEUR PROCEDE DE PRODUCTION (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF)

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 1,828,216
Patent Title: DERIVES DE BENZENE SUBSTITUES PAR GLUCOPYRANOSYLE, MEDICAMENTS CONTENANT CES COMPOSES, LEUR UTILISATION ET LEUR PROCEDE DE FABRICATION (GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE)

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,295,422
Patent Title: Dérivés de benzol substitués par glucopyranosyl, médicament contenant ces composés, leur utilisation et leur procédé de fabrication (Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production)

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,360,164
Patent Title: Derives de benzene substitues par glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de fabrication (Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof)

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: European Patent Office Patent 2,360,165
Patent Title: Derives du benzol substitues par un glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de production (Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture)

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: European Patent Office Patent 1,729,736
Patent Title: FORMULATIONS GALENIQUES DE COMPOSES ORGANIQUES (GALENIC FORMULATIONS OF ORGANIC COMPOUNDS)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: European Patent Office Patent 2,283,826
Patent Title: Formulations galéniques de composés organiques (GALENIC FORMULATIONS OF ORGANIC COMPOUNDS)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: European Patent Office Patent 1,729,819
Patent Title: DISPOSITIF D'ADMINISTRATION DE MEDICAMENTS VISIBLE AUX RAYONS X (X-RAY VISIBLE DRUG DELIVERY DEVICE)

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: European Patent Office Patent 1,732,628
Patent Title: APPAREIL D'ADMINISTRATION DE MEDICAMENT COMPRENANT UN ENSEMBLE ENGRENAGE PRESENTANT UN ORIFICE CONTENANT UN ELEMENT DE COMMANDE (MEDICATION DISPENSING APPARATUS WITH GEAR SET HAVING DRIVE MEMBER ACCOMMODATING OPENING)

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: European Patent Office Patent 1,732,629
Patent Title: APPAREIL D'ADMINISTRATION DE MEDICAMENT COMPRENANT UNE CARACTERISTIQUE DE VERROUILLAGE AU MOYEN D'UN RESSORT POUR L'ADMINISTRATION D'UNE DOSE FINALE (MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE)

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: European Patent Office Patent 1,732,890
Patent Title: CORPS POLYMORPHE CRISTALLIN DE BASEDOXIFÈNE AC TATE (CRYSTALLINE POLYMORPH OF A BAZEDOXIFENE ACETATE)

DUAVEE is a drug marketed by Wyeth Pharms. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: European Patent Office Patent 1,740,163
Patent Title: PREPARATION CONTRACEPTIVE A PLUSIEURS PHASES A BASE D'UN OESTROGENE NATUREL (MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN)

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: naltrexone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2024
Generic Entry Controlled by: European Patent Office Patent 1,740,120
Patent Title: COMPOSITIONS DE NALTREXONE, À ACTION LONGUE DURÉE ET MÉTHODE D'UTILISATION (NALTREXONE LONG ACTING FORMULATIONS AND METHODS OF USE)

VIVITROL is a drug marketed by Alkermes. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

Generic name: naltrexone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2024
Generic Entry Controlled by: European Patent Office Patent 2,386,269
Patent Title: Formulation de naltrexone à action prolongée et procédés d'utilisation (Naltrexone long acting formulations and methods of use)

VIVITROL is a drug marketed by Alkermes. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: European Patent Office Patent 1,740,177
Patent Title: ANTAGONISTES DES RECEPTEURS MUSCARINIQUES DE L'ACETYLCHOLINE (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: European Patent Office Patent 2,570,128
Patent Title: Antagonistes des récepteurs muscariniques de l'acétylcholine (Muscarinic acetylcholine receptor antagonists)

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: European Patent Office Patent 3,111,936
Patent Title: ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES DE L'ACÉTYLCHOLINE (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: European Patent Office Patent 1,746,999
Patent Title: 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES (4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES)

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 1,756,079
Patent Title: SYNTHESE DE CETO-EPOXYDES D'ACIDES AMINES (SYNTHESIS OF AMINO ACID KETO-EPOXIDES)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 1,758,921
Patent Title: COMPOSES D'INHIBITION ENZYMATIQUE PROTEASOME (COMPOUNDS FOR PROTEASOME ENZYME INHIBITION)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,353
Patent Title: COMPOSITION DESTINEE A INHIBER LE PROTEASOME (COMPOSITION FOR PROTEASOME INHIBITION)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 2,030,981
Patent Title: Composés pour l'inhibition d'une enzyme de proteasome (Compounds for proteasome enzyme inhibition)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 2,260,835
Patent Title: Composition destinée a inhiber le proteasome (Composition for proteasome inhibition)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 2,261,236
Patent Title: Composition destinée à inhiber le protéasome (Composition for proteasome inhibition)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: European Patent Office Patent 2,564,834
Patent Title: Composés pour l'inhibition d'une enzyme du protéasome (Compounds for Proteasome Enzyme Inhibition)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: European Patent Office Patent 1,747,036
Patent Title: Dispositif d'inhalation (Inhaler device)

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: European Patent Office Patent 1,747,036
Patent Title: Dispositif d'inhalation (Inhaler device)

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: European Patent Office Patent 1,636,190
Patent Title: CRISTAL STABLE DE COMPOSE 4-OXOQUINOLINE (STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-four patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: European Patent Office Patent 2,514,746
Patent Title: Cristal stable de composé 4-oxoquinoline (Stable crystal of 4-oxoquinoline compound)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-four patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: European Patent Office Patent 3,281,939
Patent Title: MÉTHODE POUR PRÉPARATION D'UN CRISTAL STABLE DE COMPOSÉ 4-OXOQUINOLINE (METHOD OF PRODUCING STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-four patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: European Patent Office Patent 1,753,431
Patent Title: COMPOSITIONS PHARMACEUTIQUES COMPORTANT ZD6474 (PHARMACEUTICAL COMPOSITIONS COMPRISING ZD6474)

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: European Patent Office Patent 1,758,631
Patent Title: APPAREIL DISTRIBUTEUR A COMPTEUR DE DOSES (DISPENSING APPARATUS WITH COUNTER)

QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: European Patent Office Patent 1,748,765
Patent Title: SUSPENSION PHARMACEUTIQUE (PHARMACEUTICAL SUSPENSION COMPOSITION)

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: European Patent Office Patent 2,465,497
Patent Title: Suspension pharmaceutique (Pharmaceutical suspension composition)

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.